Atlas Trials

Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia

Clinical trial NCT02136511 · APPROVED_FOR_MARKETING

Trial details

NCT number
NCT02136511
Sponsor
Gilead Sciences
Status
APPROVED_FOR_MARKETING
Study type
EXPANDED_ACCESS
Chronic Lymphocytic Leukemia (CLL)

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.